Provided by Tiger Trade Technology Pte. Ltd.

Rocket Pharmaceuticals, Inc.

3.48
+0.07002.05%
Post-market: 3.530.0500+1.44%19:30 EDT
Volume:2.64M
Turnover:9.21M
Market Cap:382.02M
PE:-20.47
High:3.57
Open:3.57
Low:3.40
Close:3.41
52wk High:5.45
52wk Low:2.53
Shares:109.77M
Float Shares:84.96M
Volume Ratio:1.53
T/O Rate:3.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1700
EPS(LYR):-2.0100
ROE:-4.77%
ROA:-28.42%
PB:1.04
PE(LYR):-1.73

Loading ...

Rocket Pharmaceuticals Price Target Cut to $15.00/Share from $16.00 by Wedbush

Dow Jones
·
Aug 11

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Sonida Senior Living (SNDA) and TELA Bio (TELA)

TIPRANKS
·
Aug 11

Wedbush Adjusts PT on Rocket Pharmaceuticals to $15 From $16, Keeps Outperform Rating

MT Newswires Live
·
Aug 11

Cantor Fitzgerald Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Aug 11

Rocket Pharmaceuticals, Inc. Expected to Post a Loss of 42 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Aug 11

Rocket Pharmaceuticals, Inc. : Leerink Partners Cuts Target Price to $7 from $12

THOMSON REUTERS
·
Aug 11

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Aug 11

Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate

Benzinga Earnings
·
Aug 11

Rocket Pharmaceuticals Posts Q2 Profit Helped by PRV Sale

Reuters
·
Aug 11

Rocket Pharma Swings to Q2 FY26 Net Income of $123.2 Million; R&D Expenses Fall 30.92% to $29.5 Million

Reuters
·
Aug 11

Rocket Pharmaceuticals Q2 EPS USD 1.08

Reuters
·
Aug 11

Rocket Pharmaceuticals, Inc.: Cash, Cash Equivalents and Investments of About $283.7 Mln; Expected Cash Runway into Q2 of 2028

THOMSON REUTERS
·
Aug 11

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

THOMSON REUTERS
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Aug 04

Rocket Pharmaceuticals Inc Expected to Post Earnings of 37 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Rocket Pharmaceuticals - Rp-A501 Well-Tolerated in Initial Three Patients with no Tma or Capillary Leak Syndrome

THOMSON REUTERS
·
Aug 03

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with Rp-A501 Under Modified Phase 2 Protocol for Danon Disease

THOMSON REUTERS
·
Aug 03

Rocket Pharmaceuticals - Engaging with FDA on Pivotal Trial; Regulatory Update Expected in H2 2026

THOMSON REUTERS
·
Aug 03

Quince Therapeutics Names Brigette Roberts CEO in Management Reshuffle

Reuters
·
Aug 01